ARC‐18 Improved Motor Performance Through Inhibiting ACLY‐Mediated Smad2/3 Acetylation in a Model of Duchenne Muscular Dystrophy
Our study indicated that oral ARC-18 treatment decelerated the progression of neuromuscular disease in a reliable DMD animal model, suggesting its potential as a promising drug for DMD.
Authors
- Yongmei Xie (ORCID: https://orcid.org/0000-0002-7913-0283)
- Bingge Zhang
- Xifei Yang (ORCID: https://orcid.org/0000-0002-9000-7016)
- Gong‐Ping Liu (ORCID: https://orcid.org/0000-0001-8501-998X)
- Chao Yang (ORCID: https://orcid.org/0000-0003-0626-0586)
- Jianjun Liu (ORCID: https://orcid.org/0000-0002-3255-3019)
- Chongyang Chen (ORCID: https://orcid.org/0000-0001-6856-3430)
- Jing Wang (ORCID: https://orcid.org/0000-0003-4896-0142)
- Ye He
- Haitao Yu (ORCID: https://orcid.org/0000-0002-2781-1642)
Institutions
- Nantong University (CN)
- Sichuan University (CN)
- National Health and Family Planning Commission (CN)
- Shenzhen Center for Disease Control and Prevention (CN)
- State Key Laboratory of Biotherapy
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Cachexia Sarcopenia and Muscle
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/jcsm.70081
- Citations
- 3
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.42